Fundz

Veralox Therapeutics Inc. reported raising $14.4 Million in an initial SEC Form D filing, from an offering of $22.8 Million

PRIVATEJul 07, 2021$14.4M of $22.8M raised

Amount Raised

$14.4 Million

$14.4 Million sold, per SEC Form D (first sale Jul 7, 2021)

Round Type

Venture

FrederickBiotechnology

Quick answer

VLX-1005 raised $14.4 Million in a funding round, dated July 7, 2021. VLX-1005 is based in Frederick, Maryland, United States.

How much did VLX-1005 raise?
VLX-1005 raised $14.4 Million in a funding round on July 7, 2021.
What does VLX-1005 do?
VLX-1005 is a Phase 2 drug candidate indicated for heparin-induced thrombocytopenia (HIT).
Where is VLX-1005 based and how big is it?
VLX-1005 is based in Frederick, Maryland, United States.

Source: Fundz verified event record.

Who else raised in Biotechnology around the same time

Companies in the same sectors as VLX-1005 that raised within 45 days of this round, from Fundz verified event records.

  • Ambagon Therapeutics raised $5.4M on August 20, 2021.
  • Circular Genomics raised $3.1M on August 20, 2021.
  • Nobell Foods raised $27M on August 20, 2021.
  • Opus Genetics raised $9.5M on August 20, 2021.
  • Gross-Wen Technologies raised $6.5M on August 20, 2021.
  • Evecxia raised $8.6M on August 20, 2021.

Who to call at VLX-1005, and when

A new round usually means VLX-1005 is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day VLX-1005 raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at VLX-1005, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at VLX-1005. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

VLX-1005

Location

Frederick, Maryland, United States

About

VLX-1005 is a Phase 2 drug candidate indicated for heparin-induced thrombocytopenia (HIT). It comes with Orphan Drug and Fast Track designations, representing a crucial step in addressing a rare but serious condition. This asset aligns with Cadrenal's strategic vision to enhance its portfolio in the anticoagulation space and improve patient outcomes. The acquisition strengthens Cadrenal's market position considerably.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment VLX-1005 raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for VLX-1005's next move

See what Strategic adds

VLX-1005 raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.